Clinical Trial Update: Cost-effectiveness Study of Symbicort as Maintenance and Reliever Therapy (SMART)

View source ↗

Summary

A completed cost-effectiveness study evaluating Symbicort as maintenance and reliever therapy (SMART) for asthma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• Symbicort (budesonide/formoterol)

Snippet

Sponsor: AstraZeneca | Conditions: Asthma | Status: COMPLETED